With only 5% of cancer drugs being approved, the financial risks to oncology programs are huge. Recently, PDX (patient-derived xenografts) have become one of the preferred approaches for preclinical drug development and biomarker discovery, but when is the best time to introduce them into your program? How can PDX be incorporated into an immuno-oncology program? Can clinical biomarkers be identified using these models?

These are just some of the questions we discuss as we provide an overview of our experience with PDX models and summarize how we can use it to help you manage your oncology preclinical programs.


  • Markus Posch, PhD, Project Manager, Charles River